Angela DeMichele, MD, MSCE, Talks Changes to the Treatment Paradigm Resulting From I-SPY2 in Early Breast Cancer
Angela DeMichele, MD, MSCE, discussed how the standard of care can be shifted based on the results of the phase 2 I-SPY2 trial investigating novel neoadjuvant treatment strategies in early breast cancer.
Angela DeMichele, MD, MSCE, Discusses Future Directions of the Phase 2 I-SPY2 Trial in Early Breast Cancer
Angela DeMichele, MD, MSCE, discussed the results of the phase 2 I-SPY2 trial in patients with early breast cancer
Angela DeMichele, MD, MSCE, Analyzes Data Thus Far From I-SPY2 in HR+/HER2– Early Breast Cancer
Angela DeMichele, MD, MSCE, discussed how the phase 2 I-SPY2 trial in patients with early breast cancer is informing patient therapy decisions in difficult-to-treat situations.
Angela DeMichele, MD, MSCE, Assesses the Value of I-SPY2 for Neoadjuvant Treatment of Early Breast Cancer
Angela DeMichele, MD, MSCE, spoke about the I-SPY2 trial, which evaluates patients with early breast cancer who are treated with experimental neoadjuvant systemic therapy regimens.
ASCO: Neoadjuvant Therapy Options and Clinical Trials in Breast Cancer
Ahead of the ASCO 2013 meeting we discuss neoadjuvant therapy options and clinical trials in breast cancer, as well as the opportunities for targeted therapies in post-neoadjuvant trials.
